06.01.16
Valensa International has introduced ovo-vegetarian Deep Ocean Caviar, an omega-3 phospholipid formulation that contains no fish oil. Deep Ocean Caviar is derived from North Atlantic Herring Roe (herring eggs) combined with algae-sourced astaxanthin and Verilla vegetarian ALA perilla seed oil.
This formula contains a high DHA-EPA ratio along with ALA omega-3, and offers support for heart, brain and eye health. Unique and sustainable forms of omega-3 are the fastest growing segment in the supplement and functional foods markets. Deep Ocean Caviar is Valensa’s response to this rapidly expanding category.
According to Dr. Rudi Moerck, Valensa CEO, “Valensa’s commitment to the environment and human health, plus the need to address chronic low level inflammation (CLLI), was a driving force behind the development of this groundbreaking ecologically sustainable formulation. The omega-3 ALA and astaxanthin content of Deep Ocean Caviar is squarely aimed at CLLI while the EPA/DHA phospholipid content targets cellular health and cellular membrane renewal. The incredibly well-managed North Atlantic herring fishery yields herring roe twice a year and is fully sustainable.”
Valensa’s formulation technology platforms include proprietary extraction (Deep Extract Supercritical CO2), formulation, delivery/bio-functionality and patented stabilization (O2B Peroxidation Blocker Stabilization).
The omega-3 fatty acids in Deep Ocean Caviar are absorbed and carried to the body’s cells in phospholipid and free fatty acid form, enabling optimal bioavailability, the company said. Deep Ocean Caviar has four condition-specific applications: brain health, eye health, joint heath and cardiovascular health and can be customized to meet condition-specific needs.
For more information: www.valensa.com
This formula contains a high DHA-EPA ratio along with ALA omega-3, and offers support for heart, brain and eye health. Unique and sustainable forms of omega-3 are the fastest growing segment in the supplement and functional foods markets. Deep Ocean Caviar is Valensa’s response to this rapidly expanding category.
According to Dr. Rudi Moerck, Valensa CEO, “Valensa’s commitment to the environment and human health, plus the need to address chronic low level inflammation (CLLI), was a driving force behind the development of this groundbreaking ecologically sustainable formulation. The omega-3 ALA and astaxanthin content of Deep Ocean Caviar is squarely aimed at CLLI while the EPA/DHA phospholipid content targets cellular health and cellular membrane renewal. The incredibly well-managed North Atlantic herring fishery yields herring roe twice a year and is fully sustainable.”
Valensa’s formulation technology platforms include proprietary extraction (Deep Extract Supercritical CO2), formulation, delivery/bio-functionality and patented stabilization (O2B Peroxidation Blocker Stabilization).
The omega-3 fatty acids in Deep Ocean Caviar are absorbed and carried to the body’s cells in phospholipid and free fatty acid form, enabling optimal bioavailability, the company said. Deep Ocean Caviar has four condition-specific applications: brain health, eye health, joint heath and cardiovascular health and can be customized to meet condition-specific needs.
For more information: www.valensa.com
